Subscribe To
IMRN / Immuron CEO highlights strong sales growth in business update presentation
IMRN News
By GlobeNewsWire
September 11, 2023
Immuron CEO, Steven Lydeamore to present at H.C. Wainwright
MELBOURNE, Australia, Sept. 11, 2023 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN), an Australian based and globally integrated biophar more_horizontal
By Market Watch
May 8, 2023
Immuron stock rockets after FDA removes hold on IND of infectious diarrhea treatment
The U.S.-listed shares of Immuron Ltd. IMRN powered up 66.3% toward a one-year high in premarket trading Monday, after the Australia-based biopharmace more_horizontal
By Proactive Investors
March 6, 2023
Immuron CEO highlights strong sales growth in business update presentation
Immuron Ltd (NASDAQ:IMRN, ASX:IMC) CEO Steven Lydeamore highlighted the strong growth in sales of oral immunotherapeutic products in the company's Fe more_horizontal
By Seeking Alpha
September 6, 2022
Immuron Limited (IMRN) Q4 2022 Earnings Call Transcript
Immuron Limited (NASDAQ:IMRN ) Q4 2022 Earnings Conference Call September 6, 2022 7:00 PM ET Company Participants Steven Lydeamore - Chief Executive O more_horizontal
By Benzinga
October 8, 2021
Immuron's IMM-124E Shows Antiviral T-Cell Immunity, Potential For COVID-19
Immuron Limited (NASDAQ: IMRN) has announced a recent publication of antiviral data from the IMM-124E preclinical and Phase 1/2a trials. The studie more_horizontal
By Benzinga
October 8, 2021
Immuron's IMM-124E Shows Antiviral T-Cell Immunity, Potential For COVID-19
Immuron Limited (NASDAQ: IMRN) has announced a recent publication of antiviral data from the IMM-124E preclinical and Phase 1/2a trials. The studie more_horizontal
By Benzinga
October 8, 2021
Immuron's IMM-124E Shows Antiviral T-Cell Immunity, Potential For COVID-19
Immuron Limited (NASDAQ: IMRN) has announced a recent publication of antiviral data from the IMM-124E preclinical and Phase 1/2a trials. The studie more_horizontal